Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings ...
Hosted on MSN1mon
Rodman & Renshaw sets Talphera stock Buy rating, $4 targetOn Tuesday, Rodman & Renshaw initiated coverage on shares of biopharmaceutical company Talphera (NASDAQ: TLPH) with a Buy rating and a price target of $4.00. The firm's analysts highlighted ...
NASDAQ:TLPH opened at $0.56 on Monday. The firm has a 50-day moving average price of $0.62 and a two-hundred day moving average price of $0.77. The company has a market capitalization of $9.53 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback